Lectin-like oxidised LDL receptor-1 as a marker of endothelial dysfunction in behçet's disease

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.77, 2013, Pages

  Ozyazgan, S ^a   Uzun, H ^a   Onal, B ^a   Tuzcu, A ^a   Ugurlu, S ^a   Andican, G ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Behcet's disease; Endothelial nitric oxide synthase; Endothelin 1; Lectin like oxidised LDL receptor 1; Nitric oxide; Oxidised LDL; Systemic lupus erythematosus

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BEHCET SYNDROME; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PREDICTIVE VALUE OF TESTS; ROC CURVE; SCAVENGER RECEPTORS, CLASS E; YOUNG ADULT;

EID: 84884957049     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. BEHçET H: Uber rezidivierende Apthose, durch ein Virus verursachte geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-7.
2. ATZENI F, SARZI-PUTTINI P, DORIA A, BOIARDI L, PIPITONE N, SALVARANI C: Behçet's disease and cardiovascular involvement. Lupus 2005; 14: 723-6.
3. MARZBAN M, MANDEGAR MH, KARIMI A et al.: Cardiac and great vessel involvement in Behçet's disease. J Card Surg 2008; 23: 765-8.
4. KOC Y, GULLU I, AKPEK G et al.: Vascular involvement in Behçet's disease. J Rheumatol 1992; 19: 402-10.
5. SCHMITZ-HUEBNER U, KNOP J: Evidence for an endothelial dysfunction in association with Behçet's disease. Thromb Res 1984; 3: 277-85.
6. Von FELDT JM: Premature atherosclerotic cardiovascular disease and systemic lupus erythematosus from bedside to bench. Bull NYU Hosp Jt Dis 2008; 66: 184-7.
7. TURANO L: Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus: understanding management strategies. J Cardiovasc Nurs 2013; 28: 48-53.
8. KUME N, KITA T: Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr Opin Lipidol 2001; 12: 419-23.
9. MORAWIETZ H: LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis. Dtsch Med Wochenschr 2010; 135: 308-12.
10. KORHONEN R, LAHTI A, KANKAANRANTA H, MOILANEN E: Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005; 4: 471-9.
11. CHAMBERS JC, HASKARD DO, KOONER JS: Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol 2001; 37: 517- 20.
12. YAPISLAR H, AYDOGAN S, BORLU M, ASCIOGLU Ö: Decreased nitric oxide and increased platelet aggregation levels in patients with Behçet's disease. Thromb Res 2007; 119: 461-5.
13. SAHIN M, ARSLAN C, NAZIROGLU M et al.: Asymmetric dimethylarginine and nitric oxide levels as a sign of endothelial dysfunction in Behçet's disease. Ann Clin Lab Sci 2006; 36: 449-54.
14. ER H, EVEREKLIOGLU C, CUMURCU T et al.: Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002; 86: 653-7.
15. TUNç R, ULUHAN A, MELIKOGLU M, OZYAZGAN Y, ÖZDOGAN H,YAZICI H: A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome. Clin Exp Rheumatol 2001; 19: 45-7.
16. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.1982; 25: 1271-7.
17. OREM A, YANDI Y, VANIZOR B, CIMSIT G, UYDU H, MALKOC M: The evaluation of autoantibodies against oxidatively modified LDL, susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease. Clinl-Biochem 2002; 35: 217-24.
18. OREM A, CIMSIT G, DEGER O, VANIZOR B, KARAHAN S: Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease. Dermatology 1999; 198: 243-6.
19. WITZTUM JL, STEINBERG D: Role of oxi dized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-91.
20. ZHAO XQ, ZHANG MW, WANG F et al.: CRP enhances soluble LOX-1 release from macrophages by activating TNF-a converting enzyme. J Lipid Res 2011; 52: 923-33.
21. TAYSI S, SARI RA, DURSUN H et al.: Evaluation of nitric oxide synthase activity, nitric oxide, and homocysteine levels in patients with active Behçet's disease. Clin Rheumatol 2008; 27: 1529-34.
22. HODEIB AA, ELSHARAWY TA, FAWZI HA: Assessment of serum homocysteine, endothelin- 1, and nitric oxide levels in Behçet's disease. Indian J Dermatol 2010; 55: 215-20.
23. BELGUENDOUZ H, MESSAOUDÈNE D, LAHMAR K et al.: Interferon-γ and nitric oxide production during Behçet uveitis: immunomodulatory effect of interleukin-10. J Interferon Cytokine Res 2011; 31: 643-51.
24. SAHIN M, ARSLAN C, NAZIROGLU M et al.: Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behçet's disease. Ann Clin Lab Sci 2006; 36: 449-54.
25. OZKAN Y, YARDIM-AKAYDIN S, SEPICI A, ENGIN B, SEPICI V, SIMSEK B: Assessment of homocysteine, neopterin and nitric oxide levels in Behçet's disease. Clin Chem Lab Med 2007; 45: 73-7.
26. YAPISLAR H, AYDOGAN S, BORLU M, ASCIOGLU O: Decreased nitric oxide and increased platelet aggregation levels in patients with Behçet's disease. Thromb Res 2007; 119: 461-5.
27. BEKPINAR S, KILIç N, UNLÜçERçI Y, AKDAG-KÖSE A, AZIZLERLI G, OZBEK-KIR Z: Evaluation of nitrosative and oxidative stress in Behçet disease. J Eur Acad Dermatol Venereol 2005; 19: 167-71..
28. HEIN TW, LIAO JC, KUO L: oxLDL specifically impairs endothelium-dependent, NOmediated dilation of coronary arterioles. Am J Physiol Heart Circ Physiol 2000; 278: H175-83.
29. URAL AU, YALCIN A, BEYAN C, ISIMER A, BAYHAN H: Plasma endothelin-1 concentrations in patients with Behçet's disease. Scand J Rheumatol 1994; 23: 322-5.
30. USLU T, EREM C, TOSUN M, DEGER O: Plasma endothelin-1 levels in Behçet's disease. Clin Rheumatol 1997; 16: 59-61.
31. CIMSIT G, KARAHAN SC, OREM A, VANIZOR B, ALPAY K: Plasma endothelin-1 levels before and after vascular occlusive test in patients with Behçet's disease. Australas J Dermatol 2001; 42: 221-2.
32. HAMZAOUI K, CHELBI H, KAMOUN M, BEN DHIFALLAH I, HAMZAOUI A: Increased endothelin- 1 levels of BAL fluid in patients with Behçet's disease. Mediators Inflamm 2007; 2007: 93726.